AI-generated analysis. Always verify with the original filing.
Allarity Therapeutics significantly reduced its operating and net losses in FY2025 through strategic cost restructuring and a narrowed clinical focus, though it remains a pre-revenue company facing substantial ongoing expenses and cash burn as it advances its lead candidate.
EPS
$-0.78
Revenue
$320.0K
Net Income
-$11.2M
free cash flow
-$14.8M
Operating Income
-$12.6M
operating margin
-3939.1%